Literature DB >> 6595969

Drug-induced cardionecrosis.

T Godfraind.   

Abstract

Cardiotoxicity may be defined as a drug action producing abnormalities in cardiac function, such as transitory disturbances or rhythm, conduction or contractility. Clearance of the drug is followed by recovery of the initial function. Cardionecrosis is the irreversible consequence of cardiotoxicity. Its appearance depends not only upon the toxicological potency of a given compound but may also depend upon the pathophysiological state of the heart. Therefore, two main categories may be recognized considering the influence of this state. Drugs may act on the processes controlling cellular structure such as protein biosynthesis in the case of antibiotics of the anthracycline group. Drugs may act at the level of metabolic regulation through a membranal or an intracellular action; in this case, the functional state of the heart plays a major role. This is mainly observed with sympathomimetics and with drugs interacting with the function of catecholamines. The cardiotoxicity observed in such conditions mimics the action of anoxia or of ischemia. The main determinant of the cardiac lesion is probably the disturbance of cellular calcium metabolism. This situation may be prevented (or treated) by the use of calcium entry blockers (calcium antagonists). A great part of this report will deal with the second group of drugs, because of their potential importance as a chemical hazard for the population and because of a possible preventive protection by calcium entry blockers (calcium antagonists).

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6595969

Source DB:  PubMed          Journal:  Arch Toxicol Suppl        ISSN: 0171-9750


  2 in total

1.  Carvedilol-Afforded Protection against Daunorubicin-Induced Cardiomyopathic Rats In Vivo: Effects on Cardiac Fibrosis and Hypertrophy.

Authors:  Wawaimuli Arozal; Flori R Sari; Kenichi Watanabe; Somasundaram Arumugam; Punniyakoti T Veeraveedu; Meilei Ma; Rajarajan A Thandavarayan; Vijayakumar Sukumaran; Arun Prasath Lakshmanan; Yoshiyasu Kobayashi; Sayaka Mito; Vivian Soetikno; Kenji Suzuki
Journal:  ISRN Pharmacol       Date:  2011-04-14

2.  Dexrazoxane-afforded protection against chronic anthracycline cardiotoxicity in vivo: effective rescue of cardiomyocytes from apoptotic cell death.

Authors:  O Popelová; M Sterba; P Hasková; T Simůnek; M Hroch; I Guncová; P Nachtigal; M Adamcová; V Gersl; Y Mazurová
Journal:  Br J Cancer       Date:  2009-07-21       Impact factor: 7.640

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.